Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Clinical trials sponsored by Suzhou Suncadia Biopharmaceuticals Co., Ltd., explained in plain language.
-
New hope for lung cancer patients who stopped responding to targeted therapy
Disease control OngoingThis study compares a new drug, SHR-A2009, with standard chemotherapy in about 500 adults with advanced EGFR-mutated non-small cell lung cancer that has worsened after EGFR-targeted treatment. The main goal is to see if SHR-A2009 delays cancer growth better than chemo. Participan…
Phase: PHASE3 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 10:54 UTC
-
New combo therapy shows promise for tough cancers
Disease control OngoingThis study tests a new drug combination (SHR-8068 plus adebrelimab and chemotherapy) as a first treatment for people with advanced stomach or esophageal cancer that cannot be removed by surgery. The goal is to see if the combination shrinks tumors. About 153 adults aged 18-75 are…
Phase: PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 10:48 UTC
-
Lung cancer combo trial pulled before enrolling any patients
Disease control TerminatedThis study was designed to test a new combination of drugs for people with advanced non-small cell lung cancer. It aimed to see if adding SHR-A1921, adebrelimab, and SHR-8068, with or without carboplatin, was safe and effective. However, the trial was withdrawn before any partici…
Phase: PHASE1, PHASE2 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 18, 2026 12:02 UTC